Which companies are researching a COVID-19 vaccine? Which companies are researching a COVID-19 vaccine? Which companies are researching a COVID-19 vaccine?

Which companies are researching a COVID-19 vaccine?

Equities 2 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  A vaccine against COVID-19 is critical for society and to get the economy back on track. We've looked at the WHO's official list of 76 vaccine candidates being tested, found the companies involved with developing them and detailed those you can trade via Saxo's trading platform. The potential is big for the company that develops the right vaccine, but it also comes with very high risk.

Health experts agree that a vaccine is key to fighting the COVID-19 global pandemic and restoring life and the economy to what it was. The fastest vaccine ever developed in human history took four years, but the community of universities and biotechnology companies feel confident that through global collaboration a COVID-19 vaccine can be ready in 18 months. The race is on. The WHO published a list of 76 vaccine candidates on 20 April and this is now the official list. We have no knowledge of which company will win the race to find a vaccine against COVID-19. But we have found all the companies with Saxo ticker codes, so that it’s easier for you to identify the companies that can offer you exposure to this potential upside. It's important to recognise that investing in this opportunity comes with very high risk as some of the companies are illiquid and have small market values. But in general the risks of developing a vaccine are high, as you are competing against many other companies and universities. More importantly a vaccine is not just a vaccine as each comes with different coverage ratio of the various mutations but also with different risk profiles for the various age cohorts.

Companies on the WHO vaccine list, which you can trade via SaxoTraderGO, ordered by market cap.

Saxo tickerCompanyReturn YTD,
pct. (LCY)
Mkt. cap
(USD mn.)
PFE:xnysPfizer Inc0.1215332
MRNA:xnasModerna Inc144.717643
600196:xsscShanghai Fosun Pharmaceutical28.511685
BNTX:xnasBioNTech SE42.610960
APDN:xnasTakara Bio Inc23.02860
4563:xtksAnGes Inc154.01881
INO:xnasInovio Pharmaceuticals Inc205.51471
NVAX:xnasNovavax Inc333.2999
ARCT:xnasArcturus Therapeutics Holdings272.2804
DVAX:xnasDynavax Technologies Corp-29.2355
VXRT:xnasVaxart Inc627.5181
IMV:xtseIMV Inc-25.5110
IBIO:xaseiBio Inc323.7107
ALT:xnasAltimmune Inc61.947
HTBX:xnasHeat Biologics Inc15.145
IPA:xtsxImmunoPrecise Antibodies Ltd32.838
EXPRS2:xomeExpres2ion Biotech Holding AB380.730

For more coronavirus trading inspiration, check the coronavirus section in SaxoTraderGO.


Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.